

August 20, 2012

Astellas Pharma Tech to Construct Building No. 8 at Takahagi Technology Center

Tokyo, August 6, 2012 - [Astellas Pharma Inc.](#) (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that it will newly construct Building No. 8 at Takahagi Technology Center, one of the sites of Astellas group company Astellas Pharma Tech Co., Ltd. (“Astellas Pharma Tech”; Representative: Shunichi Hirashima).

Astellas is pursuing a global category leader (“GCL”) business model which is capable of supplying high valued-added drugs, backed by a high level of expertise, to select therapeutic areas with a high degree of unmet medical needs. Recently, Astellas selected and has especially focused on oncology as its third GCL area after urology and transplantation, areas in which it already is established as a GCL. Once completed, Building No. 8 will greatly enhance Astellas’ capacity to manufacture and ensure the stable supply of investigational drug substance used in high pharmaceutical activities, in which demand is predicted to increase in association with Astellas’ enrichment of its development pipeline focused on oncology.

The newly constructed Building No. 8 will have seven stories above ground and a total floor area of approximately 4,170 m². It will meet the current global Good Manufacturing Practice (GMP) for clinical trial material and is equipped with flexible facilities capable of supporting a multiple lineup of manufacturing items and changes in volumes of the demand of investigational drug substance. Further, as high potency compounds are to be manufactured at Building No. 8, the facility will be constructed with careful consideration of occupational health and safety and environmental preservation by introducing equipment with containment performance and an earthquake-absorbing structure.

After a groundbreaking ceremony on August 22, 2012, construction will be initiated in August and is scheduled for completion in late July, 2013. Total construction cost of the facility is approximately ¥ 4.2 billion.

Takahagi Technology Center is taking a lead function in drug substance through its chemical technology and innovative equipment/facilities in the Astellas Group by manufacturing drug substance for ethical pharmaceutical products and for clinical trial material. At the same time, Takahagi Technology Center aims to operate as a company in harmony with its local community through its safety, environmental and social contribution activities.

(References)

[Profile of Building No. 8]

- (1) Location : Takahagi Technology Center of Astellas Pharma Tech Co., Ltd.
(160-2, Akahama, Takahagi, Ibaraki)
- (2) Number of stories : 7 stories above ground
Total floor area : Approximately 4,170 m²
- (3) Total construction cost : Approximately ¥4.2 billion
- (4) Construction starts: August 22, 2012 (Groundbreaking Ceremony)
Date of completion : Late July, 2013

[Profile of Takahagi Technology Center]

- Foundation : April 2011
- Location : 160-2, Akahama, Takahagi, Ibaraki
- Representative : Kouji Takaoka (General Manager of Takahagi Technology Center)
- Number of employees : Approximately 140 (as of April 1, 2012)
- Business sites : Takahagi Technology Center (Takahagi, Ibaraki),
Kashima-Takahagi Technology Center (Yodogawaku-ku, Osaka)
- Businesses description: Manufacturing of drug substance for foreign and domestic ethical
Pharmaceutical products
Manufacturing of investigational drug substance

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com/en/